Framework Ventures IV L.P. Acquires Significant Stake in NovaBay Pharmaceuticals, Inc.

Framework Ventures IV L.P., along with its affiliates, has filed a Schedule 13D indicating the acquisition of a significant stake in NovaBay Pharmaceuticals, Inc. The filing reveals that Framework Ventures IV L.P. and related entities now beneficially own approximately 16.2% of NovaBay's common stock, equivalent to 1,164,117 shares. This ownership is primarily through the acquisition of Series D Preferred Stock, which is convertible into common stock. The filing also details a Securities Purchase Agreement with David Lazar, the CEO of NovaBay, for the purchase of Series D and Series E Preferred Stock. The transaction is contingent on stockholder approval at NovaBay's 2025 Annual Meeting. The filing underscores Framework Ventures' intent to engage with NovaBay's management and board to explore strategic opportunities aimed at enhancing shareholder value.